vs

Side-by-side financial comparison of HARVARD BIOSCIENCE INC (HBIO) and ATRenew Inc. (RERE). Click either name above to swap in a different company.

ATRenew Inc. is the larger business by last-quarter revenue ($43.2M vs $23.7M, roughly 1.8× HARVARD BIOSCIENCE INC). ATRenew Inc. runs the higher net margin — 16.9% vs -12.0%, a 28.9% gap on every dollar of revenue.

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

ATRenew Inc. operates a leading pre-owned consumer electronics transaction and servicing ecosystem primarily in China. Its core services include end-to-end device recycling, professional quality inspection, certified refurbishment, and resale of smartphones, laptops, tablets and other digital products, serving both individual consumers and enterprise clients across domestic and select Southeast Asian markets.

HBIO vs RERE — Head-to-Head

Bigger by revenue
RERE
RERE
1.8× larger
RERE
$43.2M
$23.7M
HBIO
Higher net margin
RERE
RERE
28.9% more per $
RERE
16.9%
-12.0%
HBIO

Income Statement — Q4 FY2025 vs Q1 FY2023

Metric
HBIO
HBIO
RERE
RERE
Revenue
$23.7M
$43.2M
Net Profit
$-2.8M
$7.3M
Gross Margin
59.7%
Operating Margin
7.2%
Net Margin
-12.0%
16.9%
Revenue YoY
-3.3%
Net Profit YoY
-15916.7%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HBIO
HBIO
RERE
RERE
Q4 25
$23.7M
Q3 25
$20.6M
Q2 25
$20.4M
Q1 25
$21.8M
Q4 24
$24.6M
Q3 24
$22.0M
Q2 24
$23.1M
Q1 24
$24.5M
Net Profit
HBIO
HBIO
RERE
RERE
Q4 25
$-2.8M
Q3 25
$-1.2M
Q2 25
$-2.3M
Q1 25
$-50.3M
Q4 24
$18.0K
Q3 24
$-4.8M
Q2 24
$-2.9M
Q1 24
$-4.7M
Gross Margin
HBIO
HBIO
RERE
RERE
Q4 25
59.7%
Q3 25
58.4%
Q2 25
56.4%
Q1 25
56.0%
Q4 24
57.1%
Q3 24
58.1%
Q2 24
57.2%
Q1 24
60.3%
Operating Margin
HBIO
HBIO
RERE
RERE
Q4 25
7.2%
Q3 25
1.0%
Q2 25
-4.0%
Q1 25
-228.1%
Q4 24
0.0%
Q3 24
-8.5%
Q2 24
-9.0%
Q1 24
-9.3%
Net Margin
HBIO
HBIO
RERE
RERE
Q4 25
-12.0%
Q3 25
-6.0%
Q2 25
-11.2%
Q1 25
-231.2%
Q4 24
0.1%
Q3 24
-21.9%
Q2 24
-12.7%
Q1 24
-19.1%
EPS (diluted)
HBIO
HBIO
RERE
RERE
Q4 25
$-0.06
Q3 25
$-0.03
Q2 25
$-0.05
Q1 25
$-1.14
Q4 24
$0.01
Q3 24
$-0.11
Q2 24
$-0.07
Q1 24
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HBIO
HBIO
RERE
RERE
Cash + ST InvestmentsLiquidity on hand
$8.6M
$228.0M
Total DebtLower is stronger
$35.9M
Stockholders' EquityBook value
$13.7M
$557.1M
Total Assets
$80.1M
$722.9M
Debt / EquityLower = less leverage
2.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HBIO
HBIO
RERE
RERE
Q4 25
$8.6M
Q3 25
$6.8M
Q2 25
$7.4M
Q1 25
$5.5M
Q4 24
$4.1M
Q3 24
$4.6M
Q2 24
$4.0M
Q1 24
$4.3M
Total Debt
HBIO
HBIO
RERE
RERE
Q4 25
$35.9M
Q3 25
$34.0M
Q2 25
$34.9M
Q1 25
$36.4M
Q4 24
$37.0M
Q3 24
$34.9M
Q2 24
$35.7M
Q1 24
$35.6M
Stockholders' Equity
HBIO
HBIO
RERE
RERE
Q4 25
$13.7M
Q3 25
$14.1M
Q2 25
$15.7M
Q1 25
$14.8M
Q4 24
$63.3M
Q3 24
$65.3M
Q2 24
$67.2M
Q1 24
$68.8M
Total Assets
HBIO
HBIO
RERE
RERE
Q4 25
$80.1M
Q3 25
$78.0M
Q2 25
$80.1M
Q1 25
$79.8M
Q4 24
$126.6M
Q3 24
$131.2M
Q2 24
$128.9M
Q1 24
$133.2M
Debt / Equity
HBIO
HBIO
RERE
RERE
Q4 25
2.61×
Q3 25
2.41×
Q2 25
2.22×
Q1 25
2.45×
Q4 24
0.58×
Q3 24
0.53×
Q2 24
0.53×
Q1 24
0.52×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HBIO
HBIO
RERE
RERE
Operating Cash FlowLast quarter
$-96.0K
Free Cash FlowOCF − Capex
$-545.0K
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HBIO
HBIO
RERE
RERE
Q4 25
$-96.0K
Q3 25
$1.1M
Q2 25
$2.8M
Q1 25
$3.0M
Q4 24
$1.7M
Q3 24
$-842.0K
Q2 24
$-846.0K
Q1 24
$1.4M
Free Cash Flow
HBIO
HBIO
RERE
RERE
Q4 25
$-545.0K
Q3 25
$877.0K
Q2 25
$2.7M
Q1 25
$2.5M
Q4 24
$1.4M
Q3 24
$-1.7M
Q2 24
$-1.7M
Q1 24
$758.0K
FCF Margin
HBIO
HBIO
RERE
RERE
Q4 25
-2.3%
Q3 25
4.3%
Q2 25
13.0%
Q1 25
11.4%
Q4 24
5.8%
Q3 24
-7.8%
Q2 24
-7.2%
Q1 24
3.1%
Capex Intensity
HBIO
HBIO
RERE
RERE
Q4 25
1.9%
Q3 25
1.0%
Q2 25
0.4%
Q1 25
2.4%
Q4 24
1.2%
Q3 24
4.0%
Q2 24
3.5%
Q1 24
2.6%
Cash Conversion
HBIO
HBIO
RERE
RERE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
95.83×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HBIO
HBIO

Instruments Equipment Software And Accessories$21.6M91%
Service Maintenance And Warranty Contracts$2.1M9%

RERE
RERE

Segment breakdown not available.

Related Comparisons